3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Completed
2
Active not recruiting
2
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
49
Stomach Neoplasms
11
Neoplasms
10
HER2-positive Breast Cancer
8
Colorectal Neoplasms
8
Neoplasm Metastasis
7
Esophageal Neoplasms
5
Triple Negative Breast Neoplasms
4
Salivary Gland Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Adenocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Meningeal Neoplasms
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Interventions
Gemcitabine
23
Cisplatin
22
durvalumab
13
pembrolizumab
8
Oxaliplatin
7
Capecitabine
7
Fluorouracil
6
Leucovorin
5
Bevacizumab
5
lenvatinib
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
Nivolumab
3
Liquid Biopsy
3
Injections
3
Folfox protocol
3
zanidatamab
2
trifluridine tipiracil drug combination
2
tremelimumab
2
tislelizumab
2
ivosidenib
2
futibatinib
2
apatinib
2
Trastuzumab
2
Taxes
2
Irinotecan
2
Immune Checkpoint Inhibitors
2
Drug Therapy
2
Carboplatin
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Biliary Tract Neoplasms
×
Trastuzumab
×
Clear all
NCT05615818
2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3
Recruiting
800 enrolled
NCT07062263
2025-07-14
TAB-2
Tata Memorial Centre
Phase 3
Recruiting
220 enrolled